XML 13 R20.htm IDEA: XBRL DOCUMENT v3.20.1
13. Restructuring Costs (Notes)
 3 Months Ended
Mar. 31, 2020
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTS

Restructuring Costs for a Facility Closure

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. From December 2018 to March 31, 2020, total expenses were $4.0 million. Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of operations. The liability of $2.9 million as of March 31, 2020 consisted of $2.7 million recorded in Accrued payroll and employee benefits and $0.2 million recorded in Other current liabilities in the Condensed Consolidated Balance Sheets.

The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions):

Balances as of December 31, 2019:
 
$
3.2

Cash payments
 
(0.3
)
Balances as of March 31, 2020:
 
$
2.9



Restructuring Costs for European and North American Reorganization

In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy.
The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. The liability of $14.0 million as of March 31, 2020 was recorded in Accrued payroll and employee benefits in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(1.5) million, in Selling, general and administrative expense of $(0.5) million and in Research and development expense of $(0.4) million in the Condensed Consolidated Statements of Income for the three months ended March 31, 2020. From November 2019 to March 31, 2020, total expenses were $22.9 million.

The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):

 
 
Life Science
 
Clinical Diagnostics
 
Total
Balances as of December 31, 2019:
 
$
6.2

 
$
19.1

 
$
25.3

Adjustment to expense
 
(0.3
)
 
(2.1
)
 
(2.4
)
Cash payments
 
(2.9
)
 
(5.7
)
 
(8.6
)
Foreign currency translation gains
 
(0.1
)
 
(0.2
)
 
(0.3
)
Balances as of March 31, 2020:
 
$
2.9

 
$
11.1

 
$
14.0